TY - JOUR TI - Intrabone infusion for allogeneic umbilical cord blood transplantation in children AU - Vairy, Stephanie AU - Louis, Isabelle AU - Vachon, Marie-France AU - Richer, Johanne AU - Teira, Pierre AU - Cellot, Sonia AU - Villeneuve, Edith AU - Haddad, Elie AU - Duval, Michel AU - Bittencourt, Henrique T2 - Bone Marrow Transplantation AB - Umbilical cord blood transplantation (UCBT) has been used to treat malignant and non-malignant diseases. UCBT offers the advantages of easy procurement and acceptable partial HLA mismatches, but also shows delayed hematopoietic and immunological recoveries. We postulated that an intrabone (IB) infusion of cord blood could provide a faster short- and long-term engraftment in a pediatric population with malignant and non-malignant hematologic diseases. We conducted this phase I-II single arm, exploratory clinical trial (NCT01711788) from 2012 to 2016 in a single center. Fifteen patients aged from 1.9 to 16.4 years received an IB UCBT. Median time to neutrophils and platelet recoveries were 18 days (range: 13-36 days) and 42 days (range: 26-107 days), respectively. Rate of severe acute GVH grade was low, with only one patient with grade III aGVH. Relapse occurred in 5 patients (38.5%) and TRM occurred in 1 patient. This leads to 6 years EFS and OS of 66.7% and 80% respectively. In conclusion, IB UCBT is safe and well-tolerated in children and hematological recovery compared similarly to the results obtained with IV UCBT. DA - 2021/04/06/ PY - 2021 DO - 10.1038/s41409-021-01275-0 DP - www.nature.com SP - 1 EP - 7 LA - en SN - 1476-5365 UR - https://www.nature.com/articles/s41409-021-01275-0 Y2 - 2021/04/07/18:08:48 ER -